acetylcholine chloride
Trade name: miochol
Approved
Oct 9, 1973
Acetylcholine is the neurotransmitter at neuromuscular junctions, at synapses in the ganglia of the visceral motor system, and at a variety of sites within the central nervous system. Whereas a great deal is known about the function of cholinergic transmission at the neuromuscular junction and at ganglionic synapses, the actions of acetylcholine in the central nervous system are not as well understood. Cholinergic system is an important system and a branch of the autonomic nervous system which plays an important role in memory, digestion, control of heart beat, blood pressure, movement and many other functions. Acetylcholine in the brain alters neuronal excitability, influences synaptic transmission, induces synaptic plasticity, and coordinates firing of groups of neurons. Miochol®-E (acetylcholine chloride intraocular solution) is used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required. — NCATS
Clinical trial activity
39 trials · 31 clinical orgs · 2 marketing orgs
Earliest trial started Jan 1, 1996 (NCT00152724)
Timeline
Indications
Approved for
Studied for
- Anemia · Phase 2
- Anemia, Sickle Cell · Phase 2
- Anesthesia and Analgesia · Early Phase 1
- Breast Neoplasms · Phase 1/Phase 2
- Coronary Artery Disease · Phase 1
- Diabetes, Gestational · Early Phase 1
- Diabetes Mellitus, Type 2 · Phase 2
- Endothelial Cells · Phase 1/Phase 2
- Endothelium · Early Phase 1
- Endothelium, Vascular · Early Phase 1
- Graft Rejection · Phase 1
- Healthy Volunteers · Phase 4
- Heart Failure · Phase 1
- HIV · Phase 1
- Hyperlipidemias · Phase 2
- Hypertension · Phase 1
- Hypertension, Pulmonary · Phase 1
- Inflammation · Phase 1
- Insulin · Phase 2
- Ischemia · Phase 1
- Leukemia · Phase 1/Phase 2
- Livedoid Vasculopathy · Phase 1
- Lymphoma · Phase 1/Phase 2
- Obesity · Early Phase 1
- Oxidative Stress · Phase 1
- Pre-Eclampsia · Early Phase 1
- Pulmonary Disease, Chronic Obstructive · Phase 1
- Vascular Diseases · Phase 1/Phase 2
- Vascular Stiffness · Early Phase 1
- Vasoconstriction · Early Phase 1
- Vasodilation · Early Phase 1
Mechanism of action
CHRM3 agonist
Indicated for miosis, M3 likely involved (main form in iris)
Approval history
- approvedOct 9, 1973
Chemistry & pharmacology
SMILES
CC(=O)OCC[N+](C)(C)C- Mol. weight
- 146.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- ChEMBLCHEMBL667 ↗
- WikipediaAcetylcholine ↗
- NCATSN9YNS0M02X ↗
- ChEMBLCHEMBL1184 ↗
Also known as
- acetylcholine
- acetylcholine
- acetylcholine
- acetylcholine
- acetylcholine
- acetylcholine
- acetylcholine
- acetylcholine
- acetylcholine
- acetylcholine chloride
- acetylcholine chloride
- acetylcholine chloride
- acetylcholine chloride
- acetylcholine chloride
- miochol
- miochol
- miochol
- miochol-e
- miochol-e
- miphtel
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06499844 | Early Phase 1 (Phase 1) | Aug 1, 2024 | University of Iowa |
| NCT05946798 | Early Phase 1 (Phase 1) | Aug 30, 2023 | University of Iowa |
| NCT05219799 | Early Phase 1 (Phase 1) | Feb 28, 2023 | University of Missouri |
| NCT05653973 | Early Phase 1 (Phase 1) | Jan 3, 2023 | University of Iowa |
| NCT05193968 | N/A | Feb 24, 2022 | Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
| NCT05946785 | Early Phase 1 (Phase 1) | Feb 1, 2021 | University of Iowa |
| NCT04918563 | N/A | Sep 15, 2020 | Semmelweis University |
| NCT04001647 | Early Phase 1 (Phase 1) | Jun 1, 2019 | Colorado State University |
| NCT03953326 | Phase 1/Phase 2 (Phase 2) | Apr 23, 2019 | Pennsylvania State University |
| NCT03972683 | Early Phase 1 (Phase 1) | Apr 16, 2019 | Colorado State University |
| NCT04777383 | N/A | Apr 1, 2019 | Linkoping University |
| NCT03738943 | Early Phase 1 (Phase 1) | Feb 7, 2019 | Colorado State University |
| NCT03446612 | Phase 2 | Oct 15, 2018 | GlaxoSmithKline |
| NCT03462017 | Phase 1 | Mar 7, 2018 | Sanofi |
| NCT01075776 | N/A | Jan 1, 2017 | University of London |
| NCT03376555 | Phase 1/Phase 2 (Phase 2) | Mar 31, 2016 | National Dairy Council, Pennsylvania State University |
| NCT02034331 | N/A | Dec 1, 2012 | Department of Veteran Affairs |
| NCT01848301 | Phase 1 | Sep 1, 2012 | University of Pittsburgh |
| NCT01162824 | N/A | Jan 1, 2011 | University of London |
| NCT01125943 | N/A | Jun 1, 2010 | Dutch Cancer Society, Radboud University |
Organizations
Research & Development (31)
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bausch & Lomb | For profit | NDA2 | Sep 22, 1993 |
| Novartis | For profit | NDA2 | Oct 9, 1973 |
| Novartis | For profit | NDA | Oct 9, 1973 |